Glenn Barney - Proteome Sciences Insider

PRM -- UK Stock  

GBp 3.86  0.06  1.53%

  VP
Mr. Glenn Barney is Vice President Business Development, USA of Proteome Sciences PLC. Glenn brings over 25 years of sales and business development experience with global life sciences companies, with strong biomarker focus. He was formerly VP Business Development at NextGen Sciences Inc. and held senior positions at Decision Biomarkers and Parkin Elmer Inc
  VP Since 2011      
44 20 7043 2116  http://www.proteomics.com
Barney holds a BA in Biology from Boston University..

Management Efficiency

The company has return on total asset (ROA) of (13.16) % which means that it has lost $13.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (16.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 9.11 M in total debt. Proteome Sciences plc has Current Ratio of 0.3 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Found 1 records

VP Since

Ibrahim JalalHikma Pharmaceuticals PLC
2008

Entity Summary

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company was incorporated in 1993 and is headquartered in London, the United Kingdom. Proteome Sciences operates under Diagnostics Research classification in UK and traded on London Stock Exchange. It employs 34 people.Proteome Sciences plc (PRM) is traded on London Stock Exchange in UK. It is located in Hamilton House and employs 34 people.

Proteome Sciences plc Leadership Team

William Dawson, Non-Executive Director
Roger McDowell, Non-Executive Director
Christopher Pearce, Chief Executive, Executive Director
Ian Pike, COO and Executive Director
Richard Dennis, Chief Commercial Officer
Malcolm Ward, Chief Technical Officer of London Research Facility
Martin Diggle, Non-Executive Director
Jeremy Haigh, CEO, Director
Josef Schwarz, Head of Projects and Production - Proteome Sciences RandD
Ursula Ney, Non-Executive Director
Glenn Barney, VP of Bus. Devel. - USA
Gee Chee, Director of Personalised Medicine
Geoffrey Ellis, Fin. Director, Company Secretary and Executive Director

Stock Performance Indicators

Current Sentiment - PRM

Proteome Sciences plc Investor Sentiment

Macroaxis portfolio users are evenly split in their perspective on investing in Proteome Sciences plc. What is your perspective on investing in Proteome Sciences plc? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
C   
Purchased over 40 shares of
few hours ago
Traded for 74.96
CRM   
Purchased a lot of shares of
few hours ago
Traded for 152.9
GM   
Purchased over 70 shares of
few hours ago
Traded for 36.03
MSFT   
Purchased over 20 shares of
few hours ago
Traded for 113.54
TWTR   
Purchased over 100 shares of
few hours ago
Traded for 29.52
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.
Search macroaxis.com